Relapsed/Refractory Multiple Myeloma (RRMM), Recurrent Multiple Myeloma that does not respond to treatment research hub

A Phase 1 Open-label, Multicenter, Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of HPN217 in Patients with Relapsed/Refractory Multiple Myeloma

This study looks at a new medicine called HPN217 for people with multiple myeloma that has come back or isn't responding to treatment. It's the first time this medicine is being given to people, and doctors want to see if it's safe, what dose works best, and how the body handles it.